Ken Griffin Lipocine Inc. Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2023

May 15, 2023
SELL
$0.3 - $0.58 $18,390 - $35,554
-61,300 Reduced 67.29%
29,800 $9,000
Q4 2022

Feb 14, 2023
BUY
$0.37 - $8.65 $6,771 - $158,295
18,300 Added 25.14%
91,100 $36,000
Q3 2022

Nov 14, 2022
SELL
$0.49 - $7.65 $7,007 - $109,395
-14,300 Reduced 16.42%
72,800 $33,000

About Lipocine Inc.

LPCN Quotes by TradingView
  • Ticker LPCN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 88,510,800
  • Market Cap $431M
  • Description
  • Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...
More about LPCN
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email